Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration

Clinical and Vaccine Immunology

Volumn 18, Issue 8, 2011, Pages 1243-1251

  Mathias Santos, Camila ^a   Rodrigues, Juliana F ^a   Sbrogio Almeida, Maria Elisabete ^b   Connell, Terry D ^c   Ferreira, Luís C S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI TYPE I HEAT LABILE ENTEROTOXIN; ESCHERICHIA COLI TYPE IIA HEAT LABILE ENTEROTOXIN; ESCHERICHIA COLI TYPE IIAB5 HEAT LABILE ENTEROTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 5; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN EDEMA; SKIN PERMEABILITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; CD8-POSITIVE T-LYMPHOCYTES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNOGLOBULIN G; INFLAMMATION; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED C57BL; OVALBUMIN; SKIN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79961115546     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00012-11     Document Type: Article

References (44)

1. Arce, S., H. F. Nawar, M. W. Russell, and T. D. Connell. 2005. Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect. Immun. 73:2718-2727. (Pubitemid 40570337)
2. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting Edge: Rapid in vivo killing by memory CD8 T Cells. J. Immunol. 171:27-31. (Pubitemid 36745269)
3. Beignon, A. S., J. P. Briand, S. Muller, and C. D. Partidos. 2001. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 102:344-351. (Pubitemid 32281163)
4. Belshe, R. B., et al. 2004. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351:2286-2294. (Pubitemid 39552744)
5. Berenson, C. S., et al. 2010. Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb (T13I). Glycobiology 20:41-54.
6. Bohlke, K., R. L. Davis et al. 2003. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112:815-820. (Pubitemid 37248689)
7. Braga, C. J. M., et al. 2008. T cell adjuvant effects of three Salmonella enterica flagellins. Braz. J. Microbiol. 39:44-49. (Pubitemid 351556193)
8. Couch, R. 2004. Nasal vaccination: Escherichia coli and Bell's palsy. N. Engl. J. Med. 350:860-861. (Pubitemid 38252532)
9. Craig, J. P. 1965. A permeability factor (toxin) found in cholera stools and culture filtrated and its neutralization by convalescent cholera sera. Nature 207:614-616.
10. Edelhoch, H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6:1948-1954.
11. Enioutina, E. Y., D. Visic, and R. A. Daynes. 2000. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine 18:2753-2767. (Pubitemid 30211584)
12. Fraser, S. A., et al. 2003. Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect. Immun. 71:1527-1537. (Pubitemid 36254341)
13. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56:1748-1753.
14. Guebre-Xabier, M., S. A. Hammond, L. R. Ellingsworth, and G. M. Glenn. 2004. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J. Virol. 78:7610-7618. (Pubitemid 38915908)
15. Guillobel, H. C., et al. 2000. Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain. Infect. Immun. 68:4349-4353. (Pubitemid 30434596)
16. Guth, B. E., et al. 1986. Production of type II heat-labile enterotoxin by Escherichia coli isolated from food and human feces. Infect. Immun. 54:587-589. (Pubitemid 17171478)
17. Guth, B. E., E. M. Twiddy, L. R. Trabulsi, and R. K. Holmes. 1986. Variation in chemical properties and antigenic determinants among type II heat-labile enterotoxins of Escherichia coli. Infect. Immun. 54:529-536. (Pubitemid 17171469)
18. Hajishengallis, G., H. Nawar, R. I. Tapping, M. W. Russell, and T. D. Connell. 2004. The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells. Infect. Immun. 72:6351-6358. (Pubitemid 39425415)
19. Hajishengallis, G., et al. 2005. Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins. Infect. Immun. 73:1343-1349. (Pubitemid 40470719)
20. Hajishengallis, G., S. Arce, C. M. Gockel, T. D. Connell, and M. W. Russell. 2005. Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections. J. Dent. Res. 84:1104-1116. (Pubitemid 43827777)
21. Holmgren, J., C. Czerkinsky, K. Eriksson, and A. Mharandi. 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2):S89-S95. (Pubitemid 36588654)
22. Holmgren, J., et al. 2005. Mucosal adjuvants and anti-infection and antiimmunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97:181-188. (Pubitemid 40326949)
23. Hunsaker, B. D., and L. J. Perino. 2001. Efficacy of intradermal vaccination. Vet. Immunol. Immunopathol. 79:1-13. (Pubitemid 32463320)
24. Kang, S. M., and R. W. Compans. 2009. Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol. Cells 27:5-14.
25. Kaplanski, C., J. Lebron, J. Wolf, and B. Ledwith. 2008. Immunotoxicological concerns for vaccines and adjuvants, p. 229-237. In D. J. Herzyk and J. L. Bussiere (ed.), Immunotoxicology strategies for pharmaceutical safety assessment. John Wiley & Sons Inc., Hoboken, NJ.
26. Lasaro, M. A., C. Mathias-Santos, J. F. Rodrigues, and L. C. Ferreira. 2009. Functional and immunological characterization of a natural polymorphic variant of a heat-labile toxin (LT-I) produced by enterotoxigenic Escherichia coli (ETEC). FEMS Immunol. Med. Microbiol. 55:93-99.
27. Lee, C. H., et al. 2010. Enhanced antigen uptake by dendritic cells induced by the B pentamer of the type II heat-labile enteroxin LT-IIa requires engagement of TLR2. Vaccine 28:3696-3705.
28. Liang, S., and G. Hajishengallis. 2010. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol. Invest. 39:449-467.
29. Magnusson, K.-E., E. Kihlström, and T. Sundqvist. 1986. Effect of cholera toxin on rat intestinal permeability assessed with fluorescent dextran 3000. FEMS Microbiol. Lett. 29:15-18. (Pubitemid 16221789)
30. Magnusson, K.-E., E. Kihlström, and T. Sundqvist. 1986. Elevation of rat intestinal permeability by enterotoxigenic Escherichia coli in comparison to non-toxigenic E. coli and Salmonella typhimurium. Application of fluorescent dextran 3000 as permeability probe. FEMS Microbiol. Lett. 34:199-204. (Pubitemid 16115770)
31. Martin, M., D. J. Metzger, S. M. Michalek, T. D. Connell, and M. W. Russell. 2000. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Infect. Immun. 68:281-287. (Pubitemid 30016708)
32. Martin, M., D. J. Metzger, S. M. Michalek, T. D. Connell, and M. W. Russell. 2001. Distinct cytokine regulation by cholera toxin and type II heat-labile toxins involves differential regulation of CD40 ligand on CD4+ T cells. Infect. Immun. 69:4486-4492. (Pubitemid 32574449)
33. Nawar, H. F., N. D. King-Lyons, J. C. Hu, R. C. Pasek, and T. D. Connell. 2010. LT-IIc, a new member of the type II heat-labile enterotoxin family encoded by an Escherichia coli strain obtained from a non-mammalian host. Infect. Immun. 78:4705-4713.
34. Nawar, H. F., S. Arce, M. W. Russell, and T. D. Connell. 2005. Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities. Infect. Immun. 73:1330-1342. (Pubitemid 40470718)
35. Nawar, H. F., S. Arce, M. W. Russell, and T. D. Connell. 2007. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect. Immun. 75:621-633. (Pubitemid 46203424)
36. Sack, D. A., S. Huda, P. K. B. Neogi, R. R. Daniel, W. M. Spira. 1980. Microtiter ganglioside enzyme-linked immunosorbent assay for Vibrio and Escherichia coli heat-labile enterotoxins and antitoxin. J. Clin. Microbiol. 11:35-40. (Pubitemid 10215030)
37. Seriwatana, J., et al. 1988. Type-II heat-labile enterotoxin-producing Escherichia coli isolated from animals and humans. Infect. Immun. 56:1158-1161.
38. Simmons, C. P., et al. 2001. Immunomodulation using bacterial enterotoxins. Scand. J. Immunol. 53:218-226. (Pubitemid 32193686)
39. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622-647.
40. Teneberg, S., T. R. Hirst, J. Ångström, and K.-A. Karlsson. 1994. Comparison of the glycolipid-binding specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: identification of a receptor-active nonganglioside glycolipid for the heat-labile toxin in infant rabbit small intestine. Glycoconj J. 11:533-540.
41. Uesaka, Y., et al. 1994. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb. Pathog. 16:71-76. (Pubitemid 24136561)
42. Verma, M., S. Majumdar, N. K. Ganguly, and B. N. Walia. 1994. Effect of Escherichia coli enterotoxins on macromolecular absorption. Gut 35:1613-1616. (Pubitemid 24339263)
43. Walker, R., and J. D. Clements. 1993. Use of heat-labile toxin of enterotoxigenic Escherichia coli to facilitate mucosal immunization. Vaccine Res. 2:1-10. (Pubitemid 23125379)
44. Zoeteweij, J. P., et al. 2006. GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant. J. Immunol. 177:1197-1207. (Pubitemid 44036624)